Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

NCT04093596 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

GENETIC: ALLO-715
BIOLOGICAL: ALLO-647
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Nirogacestat

Sponsor

Allogene Therapeutics